A Look At Cabot (CBT) Valuation After Recent Share Price Momentum

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.

Cabot stock overview after recent performance shift

Cabot (CBT) has drawn fresh attention after a recent move that left the shares with a month return of 3.7% and a past 3 months return of 7.5%.

See our latest analysis for Cabot.

At a share price of $76.86, Cabot’s recent 1 month share price return of 3.7% sits alongside a year to date share price return of 14.6% and a 5 year total shareholder return of 49.0%. This points to momentum that has been building over a longer horizon even as near term moves remain relatively moderate.

If you are weighing Cabot’s recent run and want a broader view of where capital is moving in materials and infrastructure, it can be useful to compare it with companies exposed to the grid upgrade theme using our 33 power grid technology and infrastructure stocks

With Cabot trading near a US$77 analyst price target yet sitting on an estimated 21% intrinsic discount, the real question is whether the market is overlooking value or already pricing in the next phase of growth.

Price-to-Earnings of 13.1x: Is it justified?

Cabot trades on a P/E of 13.1x and is also 20.9% below an estimated fair value of $97.17 based on the SWS DCF model, compared with a last close of $76.86.

The P/E multiple compares the current share price with earnings per share and is a common yardstick for companies in chemicals and other mature industries. For Cabot, this sits alongside high quality earnings, a high 20.5% return on equity and a history of becoming profitable over the past five years with strong earnings growth over that period.

Against peers, the contrast is clear. Cabot’s 13.1x P/E is flagged as good value versus a peer average of 21.5x and the wider US Chemicals industry average of 31.6x. This suggests the market is pricing Cabot at a lower earnings multiple than many comparables, while its DCF value points to a higher underlying value based on projected cash flows.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-Earnings of 13.1x (UNDERVALUED)

However, the picture can change quickly if demand for specialty chemicals softens or if higher input and energy costs start to squeeze those currently high margins.

Find out about the key risks to this Cabot narrative.

Another view: DCF keeps the pressure on

If the P/E of 13.1x suggests Cabot is inexpensive next to peers, the SWS DCF model reinforces that view. With an estimated fair value of $97.17 versus a $76.86 share price, the stock is flagged as 20.9% undervalued on cash flow assumptions. So which signal should carry more weight for you?

Story Continues

Look into how the SWS DCF model arrives at its fair value.CBT Discounted Cash Flow as at Apr 2026

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Cabot for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 53 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With mixed signals on value and expectations, the key question is what stands out to you in the risk and reward balance. Act while the data is fresh and shape your own view by weighing the 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If Cabot has caught your eye, do not stop there. Broaden your watchlist with other ideas that could fit different roles in your portfolio.

Target potential value opportunities by scanning companies flagged as high quality and potentially mispriced using the 53 high quality undervalued stocks. Strengthen your income stream by focusing on businesses filtered for yield and resilience through the 14 dividend fortresses. Prioritise capital preservation by concentrating on companies assessed with lower risk profiles using the 72 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include CBT.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments